9-O-Demethylmitragynine (9-ODM): general
9-ODM is short for 9-O-demethylmitragynine: PubChem files it as “9-O-Demethylmitragynine” and lists “9-Hydroxycorynantheidine” among its other names.[1] It is mitragynine, the main alkaloid of the kratom leaf, with one methyl group taken off; the mitragynine entry covers the parent compound, and this entry's chemistry section shows the difference. This page is a summary of what is known and what is not. It is not medical advice and it gives no amounts.
How it relates to mitragynine and 7-OH
The body makes 9-ODM from mitragynine.[2] A study of human liver enzymes in the laboratory found that “9-O-demethylmitragynine is a major metabolite formed from mitragynine metabolism (36 % total metabolism) and displays similar pharmacologic activity”.[2] In blood samples from four regular kratom users in a 2026 clinical study, it was one of the two main breakdown products: “mitragynine 16-carboxylic acid and 9-hydroxycorynantheidine being the major circulating metabolites of mitragynine in plasma upon kratom oral administration”.[3] So anyone who uses kratom is already exposed to some 9-ODM.[3] What is new in 2026 is tablets sold as 9-ODM itself.[4]
7-OH (7-hydroxymitragynine) is a different compound: another mitragynine derivative, changed at a different position, and the subject of the federal scheduling notices of 2026.[5] 9-ODM is not 7-OH and is not a stronger or weaker form of it: PubChem records them as separate compounds.[1] The two have only this in common: each is made from mitragynine, and each acts at the mu-opioid receptor, the receptor morphine acts on.[6][5] The other relatives sold on the same shelves, MGM-15, MGM-16 and mitragynine pseudoindoxyl, are separate compounds as well. The successors piece covers all of them.
What is known about its effects
Almost everything comes from one 2006 study in animal tissue. It made the compound in the laboratory (it “is synthesized from mitragynine”) and found that “Receptor binding assays revealed that 9-hydroxycorynantheidine has high affinity for mu-opioid receptors”.[6] In strips of guinea-pig gut, “its maximum inhibition was weaker than that of mitragynine and its effect was antagonized by naloxone”.[6] That is the pattern of a partial opioid agonist: it switches the receptor on, but not all the way, and naloxone, the overdose-reversal drug, blocks it in that tissue.
What is not known
No study has given 9-ODM to people.[7] A PubMed search on 2026-11-21 for its three scientific names returned eight records: tissue and receptor work, metabolism studies, and methods for measuring it in blood and urine.[7] None tested it as a drug in humans. That means there is no published human information on what it does at any amount, how long it lasts, what it does to breathing, how it interacts with other drugs, or what happens when someone who uses it daily stops.[7] “Partial agonist” describes one tissue test. It is not a safety finding about people.
Names on the pack: MIT-9, 9ODM, C9
Since mid-2026 tablets have been sold under the names 9-ODM, 9ODM, MIT-9, MIT9 and C9.[4][8] Buyers used C9 for them: asked about one 9-ODM tablet in September 2026, a buyer answered “it's c9 which is very unimpressive”.[8] These are pack names, not chemical names.
The same name can mean two things. One retailer's blog says “MIT-9 is retail shorthand for 9-ODM (9-O-desmethylmitragynine), which scientists also call 9-hydroxycorynantheidine”.[4] Another retailer's listing for a tablet sold as MIT-9 says the opposite: “MIT-9 is the proprietary formulation name used by Stack”, and “It should not automatically be interpreted as another name for mitragynine, M9, 7OH, mitragynine pseudoindoxyl or MGM-15”.[9] A pack that says MIT-9 therefore does not tell a buyer which compound is inside. Laboratory certificates linked from the listings of one brand's MIT-9 tablets found mitragynine, and on the line for “9-OH Corynantheidine (9-O-Desmethyl Mitragynine)” or “9-O-desmethyl Mitragynine”, nothing detected.[10][11] The successors piece, the decoder of product names and the deep dive MIT-9, 9ODM, C9: what the 9-ODM tablets say on the pack, and what their certificates measured go through them.
Dependence, tolerance and withdrawal
There are no data on dependence or withdrawal for 9-ODM in people.[7] What follows is the evidence for its class, labelled as such: an inference from how the compound acts, not a finding about this compound.
The World Health Organization describes the physical features of opioid dependence as including “increased tolerance to the effects of opioids” and “withdrawal symptoms following cessation or reduction in use”.[12] The closest relative with a record, 7-OH, has followed that pattern in people.[5] The American College of Medical Toxicology reported in 2026 that “individuals using 7-OH have developed dependence, tolerance, and withdrawal typical of other opioids”.[5] The FDA's 2025 assessment states that “7-OH produces respiratory depression, physical dependence, and withdrawal symptoms characteristic of classical opioids such as morphine, fentanyl, oxycodone, and hydrocodone”.[13]
9-ODM acts at the same receptor.[6] Until someone studies it, the safer assumption is that daily use can lead to tolerance, dependence and withdrawal, as with other opioids. For 7-OH, the toxicologists note that “Cases of 7-OH withdrawal and dependence have been successfully treated using medications for opioid use disorder such as buprenorphine or methadone”,[5] which is worth knowing for anyone who finds stopping hard. Their advice to the public includes: “obtain naloxone and learn how to administer it in case of overdose”.[5] Naloxone blocked 9-ODM in the 2006 tissue study,[6] but no one has tested it against a 9-ODM overdose in a person.
The interactions section covers what happens when it is combined with alcohol, benzodiazepines, other opioids and gabapentinoids. The legal section covers where it is named in law.
References
- 9-O-Demethylmitragynine, PubChem compound record CID 10927114 — National Center for Biotechnology Information, PubChem
- An in vitro evaluation on metabolism of mitragynine to 9-O-demethylmitragynine (Melchert, Zhang and Markowitz, Chemico-Biological Interactions 2024) — PubMed (US National Library of Medicine)
- Simultaneous quantification of seventeen kratom alkaloids and metabolites in human plasma and its application to clinical pharmacokinetic sample analysis (Kanumuri et al., Pharmaceutical Biology 2026) — PubMed (US National Library of Medicine)
- What Is MIT-9? 9-ODM and Its Scientific Names Explained (retailer blog post, 2026-11-01; Wayback Machine copy) — Kures Apothecary (kures.co), archived 2026-11-02
- ACMT Position Statement: Public Health Concerns Associated with 7-Hydroxymitragynine and Other Kratom Compounds (approved August 2026) — American College of Medical Toxicology
- Partial agonistic effect of 9-hydroxycorynantheidine on mu-opioid receptor in the guinea-pig ileum (Matsumoto et al., Life Sciences 2006) — PubMed (US National Library of Medicine)
- PubMed search for 9-hydroxycorynantheidine OR 9-O-desmethylmitragynine OR 9-O-demethylmitragynine (run 2026-11-21: eight records; none gives the compound to people) — PubMed (US National Library of Medicine)
- Anyone tried KD's 9-ODM?, r/7_hydroxymitragynine — Reddit, 2026-09-24, read through the Arctic Shift archive
- Stack'd Essential MIT-9 Tablets (retailer listing; Wayback Machine copy) — Burman's Health Shop, archived 2026-11-19
- NN Analytics certificate of analysis 2608-132, Tranqx Supreme Metabolites Vanilla Mint (sold as MIT-9), tested 2026-08-18 (Wayback Machine copy of the PDF): mitragynine the main alkaloid, 9-OH corynantheidine not detected — NN Analytics, San Diego; linked from a retailer listing
- FESA Labs certificate of analysis 100061023-4, Tranqx Blue Razz, issued 2026-10-25 (Wayback Machine copy of the PDF): mitragynine the main alkaloid, 9-O-desmethyl mitragynine not detected — FESA Labs, Santa Ana; linked from a retailer listing
- Opioid overdose (fact sheet) — World Health Organization
- 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat (July 2025; copy hosted by NDEWS, University of Florida) — US Food and Drug Administration
Comments
Sign in to join the conversation.
No comments yet.